COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).

Jorga, K M

COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). [electronic resource] - British journal of clinical pharmacology Sep 1999 - 449-52 p. digital

Publication Type: Clinical Trial; Journal Article

0306-5251

10.1046/j.1365-2125.1999.00027.x doi


Aged
Antiparkinson Agents--pharmacokinetics
Benzophenones--pharmacology
Carbidopa--pharmacokinetics
Catechol O-Methyltransferase--metabolism
Catechol O-Methyltransferase Inhibitors
Drug Combinations
Drug Interactions
Enzyme Inhibitors--pharmacology
Female
Humans
Levodopa--therapeutic use
Male
Middle Aged
Nitrophenols
Parkinson Disease--drug therapy
Tolcapone